Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Sep;74(6):906–909. doi: 10.1038/bjc.1996.455

Confocal microscopy of idarubicin localisation in sensitive and multidrug-resistant bladder cancer cell lines.

P M Duffy 1, M C Hayes 1, A Cooper 1, C J Smart 1
PMCID: PMC2074719  PMID: 8826856

Abstract

Idarubicin is a highly lipophilic anthracycline and appears effective against tumours resistant to conventional anthracyclines. Confocal microscopy demonstrates predominantly cytoplasmic idarubicin accumulation. This distribution is unaltered by resistance status or the resistance reversing agent verapamil. Our results contrast with studies on conventional anthracyclines and suggest that nuclear accumulation may not be a prerequisite for anthracycline cytotoxicity.

Full text

PDF
909

Images in this article

907Figure 1
on p.907
907Figure 2
on p.907
908Figure 3
on p.908

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berman E., McBride M. Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Blood. 1992 Jun 15;79(12):3267–3273. [PubMed] [Google Scholar]
  2. Coley H. M., Amos W. B., Twentyman P. R., Workman P. Examination by laser scanning confocal fluorescence imaging microscopy of the subcellular localisation of anthracyclines in parent and multidrug resistant cell lines. Br J Cancer. 1993 Jun;67(6):1316–1323. doi: 10.1038/bjc.1993.244. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Duffy P. M., Hayes M. C., Gatrell S. K., Cooper A., Smart C. J. Determination and reversal of resistance to epirubicin intravesical chemotherapy. A confocal imaging study. Br J Urol. 1996 Jun;77(6):824–829. doi: 10.1046/j.1464-410x.1996.09539.x. [DOI] [PubMed] [Google Scholar]
  4. Floyd J. W., Lin C. W., Prout G. R., Jr Multi-drug resistance of a doxorubicin-resistant bladder cancer cell line. J Urol. 1990 Jul;144(1):169–171. doi: 10.1016/s0022-5347(17)39403-x. [DOI] [PubMed] [Google Scholar]
  5. Gervasoni J. E., Jr, Fields S. Z., Krishna S., Baker M. A., Rosado M., Thuraisamy K., Hindenburg A. A., Taub R. N. Subcellular distribution of daunorubicin in P-glycoprotein-positive and -negative drug-resistant cell lines using laser-assisted confocal microscopy. Cancer Res. 1991 Sep 15;51(18):4955–4963. [PubMed] [Google Scholar]
  6. Lankelma J., Mülder H. S., van Mourik F., Wong Fong Sang H. W., Kraayenhof R., van Grondelle R. Cellular daunomycin fluorescence in multidrug resistant 2780AD cells and its relation to cellular drug localisation. Biochim Biophys Acta. 1991 Jul 10;1093(2-3):147–152. doi: 10.1016/0167-4889(91)90116-f. [DOI] [PubMed] [Google Scholar]
  7. Michieli M., Damiani D., Michelutti A., Candoni A., Masolini P., Scaggiante B., Quadrifoglio F., Baccarani M. Restoring uptake and retention of daunorubicin and idarubicin in P170-related multidrug resistance cells by low concentration D-verapamil, cyclosporin-A and SDZ PSC 833. Haematologica. 1994 Nov-Dec;79(6):500–507. [PubMed] [Google Scholar]
  8. Moscow J. A., Schneider E., Cowan K. H. Multidrug resistance. Cancer Chemother Biol Response Modif. 1993;14:98–117. [PubMed] [Google Scholar]
  9. Plosker G. L., Faulds D. Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy. Drugs. 1993 May;45(5):788–856. doi: 10.2165/00003495-199345050-00011. [DOI] [PubMed] [Google Scholar]
  10. Roepe P. D. Analysis of the steady-state and initial rate of doxorubicin efflux from a series of multidrug-resistant cells expressing different levels of P-glycoprotein. Biochemistry. 1992 Dec 22;31(50):12555–12564. doi: 10.1021/bi00165a003. [DOI] [PubMed] [Google Scholar]
  11. Scheffer G. L., Wijngaard P. L., Flens M. J., Izquierdo M. A., Slovak M. L., Pinedo H. M., Meijer C. J., Clevers H. C., Scheper R. J. The drug resistance-related protein LRP is the human major vault protein. Nat Med. 1995 Jun;1(6):578–582. doi: 10.1038/nm0695-578. [DOI] [PubMed] [Google Scholar]
  12. Zaman G. J., Flens M. J., van Leusden M. R., de Haas M., Mülder H. S., Lankelma J., Pinedo H. M., Scheper R. J., Baas F., Broxterman H. J. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):8822–8826. doi: 10.1073/pnas.91.19.8822. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES